Assembly Biosciences (NASDAQ:ASMB) Stock Price Down 6.3% – Here’s Why

Assembly Biosciences, Inc. (NASDAQ:ASMB) shares fell 6.3% during trading on Thursday . The stock traded as low as $31.02 and last traded at $30.80. Approximately 80,476 shares were traded during mid-day trading, a decline of 52% from the average daily volume of 167,561 shares. The stock had previously closed at $32.87.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on ASMB shares. Zacks Research raised Assembly Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. Mizuho set a $53.00 target price on shares of Assembly Biosciences in a research note on Tuesday, September 1st. Guggenheim reiterated a “buy” rating and set a $43.00 price objective on shares of Assembly Biosciences in a research note on Thursday, May 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a report on Friday, July 17th. Finally, UBS Group initiated coverage on Assembly Biosciences in a research note on Tuesday, September 1st. They issued a “buy” rating and a $52.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $45.60.

Assembly Biosciences Stock Down 5.4%

The stock has a 50-day moving average of $29.68 and a 200 day moving average of $28.36. The stock has a market cap of $632.99 million, a PE ratio of 30.48 and a beta of 1.13.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.52. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%.The company had revenue of $13.37 million during the quarter, compared to analysts’ expectations of $8.60 million. Research analysts forecast that Assembly Biosciences, Inc. will post 2.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ASMB. Engineers Gate Manager LP raised its position in Assembly Biosciences by 88.5% in the second quarter. Engineers Gate Manager LP now owns 17,766 shares of the biopharmaceutical company’s stock valued at $488,000 after purchasing an additional 8,343 shares during the period. Squarepoint Ops LLC increased its position in shares of Assembly Biosciences by 43.7% during the second quarter. Squarepoint Ops LLC now owns 34,214 shares of the biopharmaceutical company’s stock valued at $940,000 after acquiring an additional 10,410 shares during the last quarter. California State Teachers Retirement System acquired a new stake in shares of Assembly Biosciences during the second quarter valued at about $103,000. Seven Fleet Capital Management LP raised its stake in shares of Assembly Biosciences by 671.5% in the 2nd quarter. Seven Fleet Capital Management LP now owns 433,147 shares of the biopharmaceutical company’s stock valued at $11,903,000 after acquiring an additional 377,000 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in Assembly Biosciences in the 2nd quarter valued at approximately $660,000. 19.92% of the stock is currently owned by hedge funds and other institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.